Dolutegravir as first- or second-line treatment for children living with HIV: 240-week follow-up of the ODYSSEY randomised trial

Abstract Background The World Health Organization recommends dolutegravir (DTG) as the anchor antiretroviral therapy (ART) drug for children living with HIV. Methods The ODYSSEY randomised trial evaluated DTG-based ART versus non-DTG standard-of-care (SOC) over 96 weeks in children starting first-line or switching to second-line ART. Participant follow-up was extended to 240 weeks; ART in extended follow-up was per national guidelines. Flexible parametric survival models estimated the proportion of participants with treatment failure on randomised allocation, accounting for treatment-switches through censoring and inverse-probability-of-censoring-weights. Adverse events were analysed in the intention-to-treat population. Results ODYSSEY enrolled 792 participants (392 DTG, 400 SOC), 311 started first-line (SOC 92% efavirenz) and 396 second-line (SOC 98% ritonavir-boosted protease inhibitors). Median (range) age at enrolment was 11.4 years (0.1-18.0), weight was 28.7 kg (3.4-85.0); 89% were from Africa. Median follow-up on randomised allocation was 286 weeks (IQR 230-310) on DTG and 204 weeks (168-240) on SOC. 23% of SOC participants switched to DTG before 192 weeks, 65% before 240 weeks. By 240 weeks, 74 participants on DTG and 131 on SOC had treatment failure (estimated 19% vs 34%: difference [DTG-SOC] -15%; 95% CI -21 to -9; P<0.001). Treatment effects were similar on first- and second-line (P=0.10). Proportions of participants with serious adverse events (52 DTG vs 53 SOC; P=0.92) or grade ≥3 adverse events (98 DTG vs 121 SOC; P=0.09) were similar by arm over 192 weeks. Conclusions DTG showed superior efficacy versus SOC over 240 weeks in children, with no safety concerns.

Authors

Institutions

Publication Details

Journal
Open Forum Infectious Diseases
Published
2026-05-01
DOI
https://doi.org/10.1093/ofid/ofag266
Primary Topic
HIV/AIDS drug development and treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Dolutegravir as first- or second-line treatment for children living with HIV: 240-week follow-up of the ODYSSEY randomised trial

Suparat Kanjanavanit, Tim Roy Cressey, Anna Turkova, Dickson Bbuye et al.
Open Forum Infectious Diseases
HIV/AIDS drug development and treatment
article

Dolutegravir as first- or second-line treatment for children living with HIV: 240-week follow-up of the ODYSSEY randomised trial

Suparat Kanjanavanit, Tim Roy Cressey, Anna Turkova, Dickson Bbuye, Grace Miriam Ahimbisibwe, Robin Kobbe, Chaiwat Ngampiyaskul, Pradthana Ounchanum, Ebrahim Variava, Srini Bandi, Moherndran Archary, Hilda Angela Mujuru, Mark Cotton, Elizabeth Kaudha, Thanyawee Puthanakit, Abbas Lugemwa, Mutsawashe Bwakura-Dangarembizi, Cissy Kityo, Adeodata R Kekitiinwa, Mariam Kasozi, Alasdair Bamford, Avy Violari, Diana M Gibb, Cristina Epaiza, Pablo Rojo, Deborah Ford, Lungile Jafta, Ellen White, Carlo Giaquinto
article en

Abstract

Abstract Background The World Health Organization recommends dolutegravir (DTG) as the anchor antiretroviral therapy (ART) drug for children living with HIV. Methods The ODYSSEY randomised trial evaluated DTG-based ART versus non-DTG standard-of-care (SOC) over 96 weeks in children starting first-line or switching to second-line ART. Participant follow-up was extended to 240 weeks; ART in extended follow-up was per national guidelines. Flexible parametric survival models estimated the proportion of participants with treatment failure on randomised allocation, accounting for treatment-switches through censoring and inverse-probability-of-censoring-weights. Adverse events were analysed in the intention-to-treat population. Results ODYSSEY enrolled 792 participants (392 DTG, 400 SOC), 311 started first-line (SOC 92% efavirenz) and 396 second-line (SOC 98% ritonavir-boosted protease inhibitors). Median (range) age at enrolment was 11.4 years (0.1-18.0), weight was 28.7 kg (3.4-85.0); 89% were from Africa. Median follow-up on randomised allocation was 286 weeks (IQR 230-310) on DTG and 204 weeks (168-240) on SOC. 23% of SOC participants switched to DTG before 192 weeks, 65% before 240 weeks. By 240 weeks, 74 participants on DTG and 131 on SOC had treatment failure (estimated 19% vs 34%: difference [DTG-SOC] -15%; 95% CI -21 to -9; P<0.001). Treatment effects were similar on first- and second-line (P=0.10). Proportions of participants with serious adverse events (52 DTG vs 53 SOC; P=0.92) or grade ≥3 adverse events (98 DTG vs 121 SOC; P=0.09) were similar by arm over 192 weeks. Conclusions DTG showed superior efficacy versus SOC over 240 weeks in children, with no safety concerns.

Open Forum Infectious Diseases
Great Zimbabwe University (ZW), University of Padua (IT), University of Zimbabwe (ZW), University of Cape Town (ZA), Chulalongkorn University (TH), Universität Hamburg (DE), University of the Witwatersrand (ZA), Great Ormond Street Hospital (GB), Great Ormond Street Hospital for Children NHS Foundation Trust (GB), University Hospitals of Leicester NHS Trust (GB), PENTA Foundation (IT), MRC Clinical Trials Unit at UCL (GB), Hospital Universitario 12 De Octubre (ES), Baylor College of Medicine Children’s Foundation (UG), University Medical Center Hamburg-Eppendorf (DE), ChiangRai Prachanukroh Hospital (TH), Prapokklao Hospital (TH), HIV Netherlands Australia Thailand Research Collaboration (TH), Health Care Foundation (CA), MUJHU Research Collaboration (UG), Children’s Foundation (GB), Joint Research Centre (DE), Nakornping Hospital (TH), Joint Clinical Research Centre (UG), University College London (GB), Chiang Mai University (TH), Bernhard Nocht Institute for Tropical Medicine (DE)
Good health and well-being
Openalex Percentile: Top 7%
HIV/AIDS drug development and treatment
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.